| Title |
Vedolizumab: First Global Approval
|
|---|---|
| Published in |
Drugs, July 2014
|
| DOI | 10.1007/s40265-014-0253-1 |
| Pubmed ID | |
| Authors |
Raewyn M. Poole |
| Abstract |
Vedolizumab [Entyvio(®) (US, Europe)], a humanized monoclonal antibody α4β7 integrin receptor antagonist, has been developed by Millennium Pharmaceuticals (d/b/a Takeda Pharmaceuticals International) for the treatment of ulcerative colitis and Crohn's disease. Vedolizumab has received its first global approval for the treatment of ulcerative colitis and Crohn's disease in the US, for use in adult patients with moderate-to-severe disease who have had an inadequate response, loss of response or intolerance to one or more standard therapies (corticosteroids, immunomodulators or tumour necrosis factor-α inhibitor) or demonstrated dependence on corticosteroids. Vedolizumab has since been approved for ulcerative colitis and Crohn's disease in the EU, Norway, Iceland and Liechtenstein. This article summarizes the milestones in the development of vedolizumab leading to its first approval for the treatment of ulcerative colitis and Crohn's disease. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 19% |
| Researcher | 7 | 17% |
| Other | 5 | 12% |
| Student > Bachelor | 4 | 10% |
| Student > Doctoral Student | 3 | 7% |
| Other | 7 | 17% |
| Unknown | 8 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 48% |
| Psychology | 3 | 7% |
| Agricultural and Biological Sciences | 2 | 5% |
| Computer Science | 2 | 5% |
| Business, Management and Accounting | 1 | 2% |
| Other | 5 | 12% |
| Unknown | 9 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2014.
All research outputs
#13,410,980
of 22,759,618 outputs
Outputs from Drugs
#2,558
of 3,251 outputs
Outputs of similar age
#110,602
of 227,682 outputs
Outputs of similar age from Drugs
#26
of 44 outputs
Altmetric has tracked 22,759,618 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,251 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,682 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.